Form 4: Lilly Endowment Inc. Sells Shares in Eli Lilly & Co.

Lilly Endowment Inc., a significant shareholder of Eli Lilly & Co., sold a portion of its holdings in multiple transactions on January 31, 2024.

Summary

• Lilly Endowment Inc. sold a total of 70,873 shares of Eli Lilly & Co. common stock on January 31, 2024.
• The sales were executed in multiple transactions at varying weighted average prices ranging from $645.282 to $662.808 per share.
• Following these transactions, Lilly Endowment Inc. still beneficially owns 99,333,810 shares of Eli Lilly & Co. common stock.
• The sales were conducted under a pre-arranged trading plan.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing detailing a share sale, with no inherent positive or negative sentiment.

Industry Context

Form 4 filings are a routine part of regulatory compliance for significant shareholders and insiders, providing transparency into their trading activities. This filing indicates a reduction in Lilly Endowment's holdings in Eli Lilly & Co.

Comparison to Industry Standards

• Form 4 filings are standard practice for reporting changes in beneficial ownership by insiders and large shareholders in publicly traded companies.
• The level of detail provided, including weighted average prices and ranges, is typical for these filings.
• The transactions are consistent with the requirements of SEC regulations.

Stakeholder Impact

• The share sale may have a minor impact on the stock price of Eli Lilly & Co., but is unlikely to be significant given the relatively small volume compared to the total shares outstanding.
• The transaction is unlikely to have any direct impact on employees, customers, or suppliers.

Key Dates

Keywords

Eli Lilly & Co, Lilly Endowment Inc, share sale, insider trading, stock transaction, Form 4, beneficial ownership